Neurological research · 2025
Trends in use of gabapentinoids among adults in the United States from 2003-2018.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chin Hok Leong
Аннотация
INTRODUCTION: This study aimed to investigate the prevalence and trends in gabapentinoid use among the US population. It also aimed to contribute to the current literature by providing additional context across different sociodemographic subgroups.
METHODS: This study utilized data from the 2003-2004 cycles to the 2017-2018 cycles, including a total of 115,554 participants aged 20 years and older. Gabapentinoid use was determined through a questionnaire that inquired about prescription medication use during the past 30 days. Analyses were weighted and conducted using STATA/SE version 17.0. Trends were assessed using logistic regression.
RESULTS: Gabapentinoid use significantly increased from 0.6% (95% CI, 0.4%-0.7%) in 2003-2004 to 1.8% (95% CI, 1.6%-2.0%) in 2017-2018, primarily driven by increased gabapentin utilization. The trends were similar across different subgroups.
CONCLUSIONS: The findings revealed a substantial rise in gabapentinoid use, particularly gabapentin, aligned with other studies. Safety concerns are underscored, emphasizing the potential for abuse and misuse, especially amid the opioid epidemic.
METHODS: This study utilized data from the 2003-2004 cycles to the 2017-2018 cycles, including a total of 115,554 participants aged 20 years and older. Gabapentinoid use was determined through a questionnaire that inquired about prescription medication use during the past 30 days. Analyses were weighted and conducted using STATA/SE version 17.0. Trends were assessed using logistic regression.
RESULTS: Gabapentinoid use significantly increased from 0.6% (95% CI, 0.4%-0.7%) in 2003-2004 to 1.8% (95% CI, 1.6%-2.0%) in 2017-2018, primarily driven by increased gabapentin utilization. The trends were similar across different subgroups.
CONCLUSIONS: The findings revealed a substantial rise in gabapentinoid use, particularly gabapentin, aligned with other studies. Safety concerns are underscored, emphasizing the potential for abuse and misuse, especially amid the opioid epidemic.